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Abstract
Background: Mortality in Zambian AIDS patients is high, especially in patients with diarrhoea, and
there is still unacceptably high mortality in Zambian patients just starting anti-retroviral therapy.
We set out to determine if high concentrations of serum cytokines correlate with mortality.
Methods: Serum samples from 30 healthy controls (HIV seropositive and seronegative) and 50
patients with diarrhoea (20 of whom died within 6 weeks) were analysed. Concentrations of
tumour necrosis factor receptor p55 (TNFR p55), macrophage migration inhibitory factor (MIF),
interleukin (IL)-6, IL-12, interferon (IFN)-γ and C-reactive protein (CRP) were measured by ELISA,
and correlated with mortality after 6 weeks follow-up.
Results: Apart from IL-12, concentrations of all cytokines, TNFR p55 and CRP increased with
worsening severity of disease, showing highly statistically significant trends. In a multivariable
analysis high TNFR p55, IFN-γ, CRP and low CD4 count (CD4 count <100) were predictive of
mortality. Although nutritional status (assessed by body mass index, BMI) was predictive in
univariate analysis, it was not an independent predictor in multivariate analysis.
Conclusion: High serum concentrations of TNFR p55, IFN-γ, CRP and low CD4 count correlated
with disease severity and short-term mortality in HIV-infected Zambian adults with diarrhoea.
These factors were better predictors of survival than BMI. Understanding the cause of TNFR p55,
IFN-γ and CRP elevation may be useful in development of interventions to reduce mortality in AIDS
patients with chronic diarrhoea in Africa.
Background
The HIV and AIDS pandemic in sub-Saharan Africa is a
major public health burden, causing high mortality and
social disruption. In urban Zambian women aged 30–34
years, HIV seroprevalence is as high as 42.5% [1].
Recently, major progress has been achieved in rolling out
highly active anti-retroviral therapy (HAART) in Zambia,
but early mortality (within 30 or even 90 days of initiating
HAART) remains a challenge [2]. The causes for this mor-
tality are unknown, but may include undiagnosed oppor-
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tunistic infections, nutritional impairment, or immune
consequences of HIV which might not respond quickly to
HAART. Even in developed countries, patients on HAART
are still at increased risk of diarrhoea [3] and in much of
sub-Saharan Africa, especially where HAART coverage is
far from complete, diarrhoeal disease remains a major
contributor to mortality.
We have previously shown that nutritional status is an
important prognostic indicator in patients with AIDS-
related diarrhoea[4], and there is a negative correlation
between circulating soluble tumour necrosis factor recep-
tors (TNFR) and nutritional status in these patients[5].
The driver of the cytokine activation remains uncertain
but it seems likely that increased intestinal mucosal per-
meability in AIDS[6] allows translocation of bacteria or
bacterial products into the portal vein, leading to Kupffer
cell activation and release of IL-1β and TNFα[7]. Translo-
cation into the lymphatic system or peritoneum can also
occur[8]. Alternatively, HIV-driven macrophage and T cell
activation may be responsible. Whatever the reason for
cytokine activation, there is evidence that cytokine activa-
tion can predict outcome in AIDS patients in Europe and
North America. In HAART-naïve Greek patients, sIL-2R in
serum predicted time to death[9]. In a multivariate analy-
sis of Spanish patients with advanced immunosuppres-
sion who had never received protease inhibitors, TNF-α
independently predicted death[10]. As most previous
work has been carried out in patients with less advanced
disease, there is a poor understanding of predictors of out-
come in patients with advanced immunosuppression, and
it is in this group that most patients with diarrhoeal dis-
ease fall. Viral load does not predict outcome particularly
well in this sub-group of patients[10]. We therefore
decided to attempt to define cytokine predictors of mor-
tality in African patients with diarrhoea. As previous work
has tended to focus on a limited number of soluble mark-
ers, we attempted to encompass a wider range of mole-
cules, including sTNFR (as a marker of TNF pathway
activation), IL-6, IL-12, macrophage migration inhibitory
factor (MIF), interferon-γ (IFN-γ) as well as C-reactive pro-
tein. We correlated concentrations of these cytokines (and
the acute phase reactant) with 6-week mortality.
Methods
Study groups
Serum samples and data were drawn from two previous
studies, one a trial of nitazoxanide in AIDS-related diar-
rhoea[11] and one a community study of small intestinal
dysfunction from which control samples were
obtained[6]. All the patients in the nitazoxanide clinical
trial were HIV positive and had chronic diarrhoea. We
therefore obtained HIV negative and positive asympto-
matic controls from the community study of small intes-
tinal dysfunction that had participants of a similar
background to those in the nitazoxanide trial. These stud-
ies were approved by the Research Ethics Committee of
the University of Zambia. They were carried out before the
roll-out of the expanded access HAART programme over
the last 2–3 years. In the nitazoxanide trial[11], no effect
on mortality was seen. A total of 80 adults over 18 years
of age, were divided into 5 groups (Table 1). Group 1 (n =
15) comprised healthy HIV seronegative adults drawn
from a cohort study in Misisi compound, Lusaka[6]. None
of these adults had evidence of infectious or digestive dis-
ease. Group 2 (n = 15) comprised HIV seropositive adults
from the same cohort, with CD4 counts less than 200
cells/μl and without a history of any diarrhoea in the
month prior to blood sampling. Groups 3–5 were drawn
from a previously reported randomised controlled trial of
nitazoxanide carried out in the University Teaching Hos-
pital, Lusaka[11]. Group 3 (n = 15) comprised adult
patients with HIV- related diarrhoea of more than one
month duration and CD4 counts of 200 cells/μl or more.
Group 4 (n = 15) comprised adults with HIV-related diar-
rhoea of over one month duration but CD4 counts under
200 cells/μl. All patients in groups 1–4 survived 6 weeks
of follow up. Group 5 (n = 20) had HIV-related diarrhoea
but died within 6 weeks of blood sampling.
Study procedures
After informed consent, patients were interviewed, had a
physical examination, nutritional anthropometry and
stool analysis performed for diarrhoea-causing intestinal
pathogens as described elsewhere[6,11]. Pre and post test
counselling for HIV was provided by a trained and experi-
enced counsellor (LN). Blood was drawn for HIV testing
and CD4 count, and aliquots of serum were stored at -
80°C for cytokine and C- reactive protein (CRP) analysis.
Table 1: Characteristics of study groups
Group* HIV status CD4 count (range) Diarrhoea BMI (kg/m2)
1 negative n/a No 24.3 (sd 5.8)
2 positive 0–200 No 21.6 (sd 1.9)
3 positive >200 Yes 16.6 (sd 2.0)
4 positive 0–200 Yes 16.5 (sd 2.5)
5 positive 0–200 Yes 16.2 (sd 2.9)
*Patients in groups 1–4 survived 6 weeks of follow up but patients in group 5 died during this period.BMC Infectious Diseases 2008, 8:156 http://www.biomedcentral.com/1471-2334/8/156
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Blood draws from participants in both studies were con-
ducted in the Gastroenterology clinic at the University
Teaching Hospital in Lusaka; all participants were fasted
and all blood samples were drawn between the hours of
0900 and 1200. Blood was collected into plain vacutain-
ers, and refrigerated in the dark for between 1 and 3 hours
until centrifugation.
All blood samples were treated the same way and col-
lected by the same people using the same equipment and
same protocol in the endoscopy unit because all these
patients and even healthy controls were having endoscop-
ies. After centrifugation, serum was separated and imme-
diately stored at -80°C in the same ultra-low freezer until
the assay was carried out. No freezer instability was expe-
rienced as Zambia has had (until now) an excellent elec-
tricity supply. This approach standardised the blood
collection and processing procedure thereby reducing var-
iation in serum cytokine levels influenced by method of
collection and processing.
ELISA was used to quantify C-reactive protein (CRP;
Kalon Biologicals, Aldershot, UK), Macrophage Migration
Inhibitory Factor (MIF; Chemicon International, Temec-
ula, Canada), Interferon-γ (IFN-γ), interleukin-12 (IL-12),
interleukin-6 (IL-6) and soluble tumour necrosis factor
receptor p55 (sTNFR; all from R&D systems, Abingdon,
UK) according to the manufacturers' instructions. Accord-
ing to the manufacturers' datasheets the thresholds of
detection of these assays were 0.2 mg/l, 1.6 ng/ml, 8.0 pg/
ml, 5.0 pg/ml, 0.7 pg/ml and 0.77 pg/ml respectively.
Statistical Analysis
Data were analysed using Stata version 8.2 (Stata Corp,
College Station, Texas). Serum concentrations of CRP and
the cytokines were not normally distributed, so analysis
was performed using the Kruskal-Wallis test across all
groups and Cuzick's non-parametric test for trend. While
the primary analysis examined significance across all five
groups, one post-hoc analysis was carried out and this was
testing for significant differences between those who died
and those who survived, using a Kruskal-Wallis test. We
performed logistic regression to determine cytokines and
their association with mortality with death at 6 weeks as a
single endpoint. We dichotomised TNFRp55, cytokines
and CRP around the median, body mass index (BMI)
around 19 kg/m2 and CD4 count around the value of 100
cells/ul. We included age and sex in the scale. To analyse
further the effect of CD4 count we created categories of
Cd4 count (<50, 50–100, 100–200, = 200 cells/μl) which
could be used in logistic regression.
Ethical considerations
The study was conducted in full accordance with the Dec-
laration of Helsinki and informed consent was obtained.
Approval for the studies was obtained from the University
of Zambia Research Ethics Committee, and the study from
which the control samples were drawn was also approved
by the Research Ethics Committee of the London School
of Hygiene and Tropical Medicine.
Results
Table 1 describes the characteristics of the study partici-
pants. Serum samples from eighty patients (51 male, 29
female, mean age 29 years) were analysed and correlated
with mortality at 6 weeks of follow-up.
Serum cytokine and TNFR p55 concentrations at baseline
Serum cytokines and CRP were all readily detected in sera
from the five groups, except for IL-12 which was below the
threshold of detection of the assay in all samples tested
and is therefore not discussed further. Concentrations of
TNFRp55 (p < 0.0001), MIF (p < 0.005), IL-6 (p < 0.01),
IFN-γ (p < 0.01), and CRP (p < 0.0001) all showed signif-
icant trends across all groups (Fig 1). Only TNFRp55 (p =
0.0001), interferon-γ (p = 0.0007) and CRP (p = 0.0001)
were significantly greater in group 5 than in the other
groups. This remained true if only patients with diarrhoea
were considered: the significance or non-significance of
each cytokine remained the same. As expected, BMI was
lower in patients who died (16.2 kg/m2, SD 2.9) than in
survivors (20.0 kg/m2, SD 4.9; p = 0.0006)
Predictors of mortality at 6 weeks
Using logistic regression with death at 6 weeks as a single
endpoint, and after dichotomising TNFRp55, cytokines
and CRP around the median, these factors, together with
body mass index <19 kg/m2, low CD4 count (CD4 count
< 100 cell/ul), age and sex were analysed. In univariate
analysis high sTNFR p55 (p = 0.001), IFN-γ (p = 0.001),
CRP (p = 0.001), low CD4+ (p = 0.0001) and BMI (p =
0.018) were associated with mortality (Table 2). In multi-
variate analysis, adjusting for CD4 count, BMI and age,
only sTNFR p55 (p = 0.033), IFN-γ (p = 0.013), CRP (p =
0.016) and low CD4 count (p = 0.01), remained inde-
pendent predictors of mortality (Table 2). Further adjust-
ment for CD4 count using categories as described in
Methods confirmed the dependence of mortality on these
biomarkers.
Discussion
There is an urgent need to identify predictive factors for
mortality in Zambian AIDS patients if we are to make any
progress in reducing mortality attributable to HIV. While
previous studies and ours have identified CD4 cell counts,
opportunistic infections, sex, age, nutritional status and
financial constraints as being associated with mortality in
Africa[12,13], other factors such as immune activation
have not been studied much in this region. A recent report
from Zimbabwe shows that sTNF-rII independently pre-BMC Infectious Diseases 2008, 8:156 http://www.biomedcentral.com/1471-2334/8/156
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The box plots show median, interquartile range, and range of serum concentrations of sTNFR p55 (1A), IFN-γ (1B) and CRP  (1C) in groups 1–5 Figure 1
The box plots show median, interquartile range, and range of serum concentrations of sTNFR p55 (1A), IFN-γ (1B) and CRP 
(1C) in groups 1–5.
A
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dicted HIV disease progression and mortality[14]. Our
data provide additional information indicating that
cytokine activation may well make a major contribution
to mortality in our patients. Of the five cytokines we stud-
ied, only IL-12 appeared not to be elevated in patients
with AIDS related diarrhoea, but IL-6 and MIF were not
directly related to mortality. The acute phase reactant CRP
was also highly discriminating as a marker of disease
severity and outcome. sTNFR p55 and interferon-γ
showed appreciable and highly significant differences
between groups of patients with AIDS related diarrhoea
and different CD4 counts (groups 3 and 4).
In systemic sepsis patients in the critical care setting, IL-6
is probably the cytokine most closely related to out-
come[15], but we did not find this. Unfortunately in that
paper, interferon-γ was not measured, but they did
observe that sTNFRp55 was a better predictor of outcome
than TNFα itself, and in previous work we have found that
sTNFRp55 correlates significantly with nutritional sta-
tus[5]. It is of interest that in multivariate analysis, nutri-
tional status was no longer predictive when cytokines
were included in a regression model and it may be that in
AIDS patients in Zambia, BMI merely reflects the effects of
cytokine activation. There is also genetic evidence that
TNF may play a causal role in HIV progression[16]. MIF
concentration was elevated in patients with AIDS related
diarrhoea, but was not independently related to mortality.
MIF is constitutively expressed by a variety of cells and tis-
sues, including monocytes and macrophages, and
released rapidly on exposure to microbial products such
as bacterial lipopolysaccharide (LPS) and TNF-α[17]. The
intracellular pools of MIF are not only released more rap-
idly than TNF-α, but are signalled to do so at concentra-
tions that are 10- to 100-fold lower than those required to
induce TNF-α production. MIF has been detected in
increased amounts in patients with severe sepsis and sep-
tic shock and has been demonstrated to be involved in
pathogenesis of shock[18]. Inhibition of MIF protects
experimental mice from lethal peritonitis[19]. It seemed
of interest as a possible correlate of mortality, but we did
not find this. The significance of CRP, which correlated
extremely well with severity of disease and with mortality
in our dataset, is probably that it behaves as a summation
of inputs from several other cytokines, notably IL-1β, IL-6
and TNF. Although it is clearly a useful discriminator in
analysing prognosis, it presents a very unlikely target for
immunotherapy.
Therapy with cytokine modulators and antagonists is
increasingly practised in many countries, beginning with
anti-TNF antibodies for rheumatoid arthritis and Crohn's
disease, and now for many other indications. In the realm
of infectious disease, therapy directed at cytokine modu-
lation has been less successful. Approaches using antibod-
ies to lipopolysaccharide were disappointing[20]. The
primary lesion which allows cytokine dysregulation has
yet to be identified, though there are grounds for believing
that it could begin with increased bacterial translocation
across the intestinal mucosal barrier[7]. The high preva-
lence of blood-borne non-typhoidal salmonellosis in
AIDS patients in Malawi lends further support to this con-
tention[21]. The significance of cytokine activation for
mortality which we describe here may suggest that it is
appropriate to draw an analogy with the situation in crit-
ical care, where systemic sepsis is associated with cytokine
over-activation.
Furthermore, cytokine activation may exacerbate the proc-
esses which gave rise to it. In this context, TNF and IL-6
can lead to increased T cell replication, presumably by up-
regulation of molecules such as CCR5 on the surface of
lymphocytes, thus facilitating viral entry. TNF also can
cause enteropathy directly[22], which may accelerate the
process of bacterial translocation. This is the rationale for
using antibodies to cytokines and chemokines in systemic
sepsis syndrome, and much work is ongoing in this area.
Therapeutic modalities which reduce bacterial transloca-
tion may be able to arrest the cycle of cytokine derange-
ments and gastrointestinal dysfunction in AIDS patients,
and clinical trials of such therapies are urgently needed.
In the results section, the box plots show wide confidence
intervals because a small number of patients showed
extremely high values.
Table 2: Factors associated with mortality
Unadjusted OR (95% CI) p Adjusted OR 95% CI p
High sTNFR p55 31.90 (3.98–255.50) 0.001 10.4 (1.04–104.0) 0.05
High IFN-γ 6.0 (1.78–20.14) 0.001 8.14(1.5–43.7) 0.01
High MIF 2.26 (0.79–6.48) 0.12 0.53 (0.12–2.3) 0.4
High CRP 15.50 (3.29–73.4) 0.001 17.10 (1.71–171.0) 0.02
Low CD4+ 13.52 (3.47–52.64) 0.0001 12.54 (1.75–89.62) 0.01
Low BMI 3.88 (1.25–12.03) 0.018 0.46(0.52–4.18) 0.50
Young age (< 40 years) 0.28 (0.67–1.17) 0.08 0.15(0.01–1.5) 0.11
Female 0.72 (0.19–2.64) 0.62 4.4 (0.39–49.2) 0.22BMC Infectious Diseases 2008, 8:156 http://www.biomedcentral.com/1471-2334/8/156
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Conclusion
High serum concentrations of TNFR p55, IFN-γ, CRP and
low CD4 count correlated with disease severity and short-
term mortality in HIV-infected Zambian adults with diar-
rhoea. These factors were better predictors of survival than
BMI. Understanding the cause of TNFR p55, IFN-γ and
CRP elevation may be useful in development of interven-
tions to reduce mortality in AIDS patients with chronic
diarrhoea in Africa.
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